SI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference

September 1, 2020

SANTA CLARA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference.

For the Morgan Stanley Global Healthcare Conference, SI-BONE's management is scheduled for a Fireside Chat on Tuesday, September 15, 2020 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

For the Cantor Global Healthcare Conference, SI-BONE's management is scheduled for a Fireside Chat on Wednesday, September 16, 2020 at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the events on the "Investors" section of the company's website at: www.si-bone.com.

About SI-BONE

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment. There are over 80 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 10825-09012020

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

Source: SI-BONE, Inc.